Show simple item record

dc.contributor.authorMonteiro, I
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorMountzios, G
dc.contributor.authorde Mello, R
dc.date.accessioned2016-03-03T14:47:25Zen
dc.date.available2016-03-03T14:47:25Zen
dc.date.issued2016-02en
dc.identifier.citationImmunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. 2016, 12 (4):551-64 Future Oncolen
dc.identifier.issn1744-8301en
dc.identifier.pmid26776915en
dc.identifier.doi10.2217/fon.15.309en
dc.identifier.urihttp://hdl.handle.net/10541/600546en
dc.description.abstractDespite recent advances, prognosis of patients with advanced lung cancer remains dismal. Owing to a better understanding of the interactions between immune system and tumor cells, immunotherapy has emerged as a promising therapeutic strategy. After the recent approval of nivolumab and the promising results with other immune checkpoint inhibitors, combination strategies are now subject of intensive research. Notwithstanding these successes, immunotherapy still holds significant drawbacks. As the target shifts from tumor cells to the tumor microenvironment, treatment paradigms are changing and several improvements are needed for optimal use in clinical practice. Robust biomarkers for patient selection and a reliable way of evaluating treatment response are high priorities. Herein we review current data on immune checkpoint inhibitors for lung cancer treatment.
dc.language.isoenen
dc.rightsArchived with thanks to Future oncology (London, England)en
dc.titleImmunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Faculty of Medicine, University of Porto, Porto, Portugalen
dc.identifier.journalFuture Oncologyen
html.description.abstractDespite recent advances, prognosis of patients with advanced lung cancer remains dismal. Owing to a better understanding of the interactions between immune system and tumor cells, immunotherapy has emerged as a promising therapeutic strategy. After the recent approval of nivolumab and the promising results with other immune checkpoint inhibitors, combination strategies are now subject of intensive research. Notwithstanding these successes, immunotherapy still holds significant drawbacks. As the target shifts from tumor cells to the tumor microenvironment, treatment paradigms are changing and several improvements are needed for optimal use in clinical practice. Robust biomarkers for patient selection and a reliable way of evaluating treatment response are high priorities. Herein we review current data on immune checkpoint inhibitors for lung cancer treatment.


This item appears in the following Collection(s)

Show simple item record